Increased multinucleated megakaryocytes as an isolated finding in bone marrow a rare finding and its Clinical significance

Majd D. Jawad, Ronald S. Go, Kaaren K. Reichard, Min Shi

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Objectives: Multinucleated megakaryocytes are a unique morphologic form of megakaryocytes characterized by multiple, distinctly separated nuclei. We investigated whether increased multinucleated megakaryocytes (≥25%) in otherwise normal-appearing bone marrow were associated with the development of a myelodysplastic syndrome (MDS). Methods: We retrospectively reviewed the medical records and bone marrow biopsy specimens of patients evaluated at our institution from 2011 to 2015 that met all of the following criteria: (1) 25% or more multinucleated megakaryocytes, (2) no other dysplastic features, (3) absence of a myeloid neoplasm, and (4) absence of neoplastic karyotypic abnormalities. Results: Nine cases of 19,885 bone marrow biopsy specimens were identified. The indications for bone marrow examination included plasma cell neoplasm, lymphoma, and cytopenia(s). All patients had anemia at the time the multinucleated megakaryocytes were found. No patients had thrombocytopenia or neoplastic karyotypic abnormalities. Follow-up was available for seven patients with a median of 27 months (range, 7-53 months). No patients developed progressive cytopenias or MDS. Conclusions: Multinucleated megakaryocytes (≥25%) as an isolated finding in the bone marrow are a rare phenomenon. These patients do not appear to be at increased risk of developing progressive cytopenia(s) or MDS. Caution should be taken to not overdiagnose these cases as MDS.

Original languageEnglish (US)
Pages (from-to)561-566
Number of pages6
JournalAmerican Journal of Clinical Pathology
Volume146
Issue number5
DOIs
StatePublished - 2016

Fingerprint

Megakaryocytes
Bone Marrow
Myelodysplastic Syndromes
Plasma Cell Neoplasms
Bone Marrow Examination
Biopsy
Thrombocytopenia
Medical Records
Anemia
Lymphoma
Neoplasms

Keywords

  • Clinical significance
  • Multinucleated megakaryocytes
  • Myelodysplastic syndrome

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Increased multinucleated megakaryocytes as an isolated finding in bone marrow a rare finding and its Clinical significance. / Jawad, Majd D.; Go, Ronald S.; Reichard, Kaaren K.; Shi, Min.

In: American Journal of Clinical Pathology, Vol. 146, No. 5, 2016, p. 561-566.

Research output: Contribution to journalArticle

Jawad, Majd D. ; Go, Ronald S. ; Reichard, Kaaren K. ; Shi, Min. / Increased multinucleated megakaryocytes as an isolated finding in bone marrow a rare finding and its Clinical significance. In: American Journal of Clinical Pathology. 2016 ; Vol. 146, No. 5. pp. 561-566.
@article{94e68b6400014a26956e828fcccbbcc2,
title = "Increased multinucleated megakaryocytes as an isolated finding in bone marrow a rare finding and its Clinical significance",
abstract = "Objectives: Multinucleated megakaryocytes are a unique morphologic form of megakaryocytes characterized by multiple, distinctly separated nuclei. We investigated whether increased multinucleated megakaryocytes (≥25{\%}) in otherwise normal-appearing bone marrow were associated with the development of a myelodysplastic syndrome (MDS). Methods: We retrospectively reviewed the medical records and bone marrow biopsy specimens of patients evaluated at our institution from 2011 to 2015 that met all of the following criteria: (1) 25{\%} or more multinucleated megakaryocytes, (2) no other dysplastic features, (3) absence of a myeloid neoplasm, and (4) absence of neoplastic karyotypic abnormalities. Results: Nine cases of 19,885 bone marrow biopsy specimens were identified. The indications for bone marrow examination included plasma cell neoplasm, lymphoma, and cytopenia(s). All patients had anemia at the time the multinucleated megakaryocytes were found. No patients had thrombocytopenia or neoplastic karyotypic abnormalities. Follow-up was available for seven patients with a median of 27 months (range, 7-53 months). No patients developed progressive cytopenias or MDS. Conclusions: Multinucleated megakaryocytes (≥25{\%}) as an isolated finding in the bone marrow are a rare phenomenon. These patients do not appear to be at increased risk of developing progressive cytopenia(s) or MDS. Caution should be taken to not overdiagnose these cases as MDS.",
keywords = "Clinical significance, Multinucleated megakaryocytes, Myelodysplastic syndrome",
author = "Jawad, {Majd D.} and Go, {Ronald S.} and Reichard, {Kaaren K.} and Min Shi",
year = "2016",
doi = "10.1093/AJCP/AQW144",
language = "English (US)",
volume = "146",
pages = "561--566",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",
number = "5",

}

TY - JOUR

T1 - Increased multinucleated megakaryocytes as an isolated finding in bone marrow a rare finding and its Clinical significance

AU - Jawad, Majd D.

AU - Go, Ronald S.

AU - Reichard, Kaaren K.

AU - Shi, Min

PY - 2016

Y1 - 2016

N2 - Objectives: Multinucleated megakaryocytes are a unique morphologic form of megakaryocytes characterized by multiple, distinctly separated nuclei. We investigated whether increased multinucleated megakaryocytes (≥25%) in otherwise normal-appearing bone marrow were associated with the development of a myelodysplastic syndrome (MDS). Methods: We retrospectively reviewed the medical records and bone marrow biopsy specimens of patients evaluated at our institution from 2011 to 2015 that met all of the following criteria: (1) 25% or more multinucleated megakaryocytes, (2) no other dysplastic features, (3) absence of a myeloid neoplasm, and (4) absence of neoplastic karyotypic abnormalities. Results: Nine cases of 19,885 bone marrow biopsy specimens were identified. The indications for bone marrow examination included plasma cell neoplasm, lymphoma, and cytopenia(s). All patients had anemia at the time the multinucleated megakaryocytes were found. No patients had thrombocytopenia or neoplastic karyotypic abnormalities. Follow-up was available for seven patients with a median of 27 months (range, 7-53 months). No patients developed progressive cytopenias or MDS. Conclusions: Multinucleated megakaryocytes (≥25%) as an isolated finding in the bone marrow are a rare phenomenon. These patients do not appear to be at increased risk of developing progressive cytopenia(s) or MDS. Caution should be taken to not overdiagnose these cases as MDS.

AB - Objectives: Multinucleated megakaryocytes are a unique morphologic form of megakaryocytes characterized by multiple, distinctly separated nuclei. We investigated whether increased multinucleated megakaryocytes (≥25%) in otherwise normal-appearing bone marrow were associated with the development of a myelodysplastic syndrome (MDS). Methods: We retrospectively reviewed the medical records and bone marrow biopsy specimens of patients evaluated at our institution from 2011 to 2015 that met all of the following criteria: (1) 25% or more multinucleated megakaryocytes, (2) no other dysplastic features, (3) absence of a myeloid neoplasm, and (4) absence of neoplastic karyotypic abnormalities. Results: Nine cases of 19,885 bone marrow biopsy specimens were identified. The indications for bone marrow examination included plasma cell neoplasm, lymphoma, and cytopenia(s). All patients had anemia at the time the multinucleated megakaryocytes were found. No patients had thrombocytopenia or neoplastic karyotypic abnormalities. Follow-up was available for seven patients with a median of 27 months (range, 7-53 months). No patients developed progressive cytopenias or MDS. Conclusions: Multinucleated megakaryocytes (≥25%) as an isolated finding in the bone marrow are a rare phenomenon. These patients do not appear to be at increased risk of developing progressive cytopenia(s) or MDS. Caution should be taken to not overdiagnose these cases as MDS.

KW - Clinical significance

KW - Multinucleated megakaryocytes

KW - Myelodysplastic syndrome

UR - http://www.scopus.com/inward/record.url?scp=85019588490&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019588490&partnerID=8YFLogxK

U2 - 10.1093/AJCP/AQW144

DO - 10.1093/AJCP/AQW144

M3 - Article

C2 - 28430954

AN - SCOPUS:85019588490

VL - 146

SP - 561

EP - 566

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

IS - 5

ER -